CPT code 38792 represents the injection procedure of a radioactive tracer specifically designed for the identification and localization of a sentinel lymph node. The sentinel lymph node is defined anatomically and physiologically as the primary or first lymph node to which cancer cells are most likely to spread from a primary tumor site. This precise mapping procedure is heavily utilized in the modern surgical management and clinical staging of various solid malignancies, most prominently breast cancer and malignant melanoma, though it is also utilized for penile, vulvar, and head and neck cancers. During the procedure, the physician or qualified healthcare professional injects a specialized radiopharmaceutical, such as Technetium-99m (Tc-99m) sulfur colloid or Tc-99m tilmanocept, directly into the tissues adjacent to the primary tumor or the previous surgical excision site. The selected injection technique and precise anatomical location can vary significantly based on the primary tumor site; for example, in breast cancer mapping, the injection may be directed peritumorally, subareolarly, intradermally, or subdermally depending on the surgeon's preference and the patient's unique anatomy. Once injected, the radioactive tracer is rapidly taken up by the local lymphatic vessels and transported sequentially to the regional lymph node basin, accumulating primarily in the sentinel node or nodes. Following a designated waiting period designed to allow for adequate lymphatic transit, the patient is typically taken to the operating room. There, the primary operating surgeon utilizes a specialized hand-held gamma detection probe to transcutaneously identify the area of highest radioactivity. This real-time auditory and visual feedback guides the precise surgical incision and the subsequent selective excision of the highly radioactive sentinel lymph node. This node is then sent for rigorous histopathological examination. Accurately identifying whether the sentinel node harbors metastatic disease is a critical determinant in the comprehensive clinical staging of the cancer. It heavily informs subsequent systemic and local treatment decisions, potentially sparing the patient the significant, lifelong morbidity associated with a complete regional lymph node dissection, such as lymphedema. It is vitally important for coders to note that CPT 38792 covers solely the administration or injection procedure itself. The actual radiopharmaceutical diagnostic agent utilized for the injection must be reported separately using appropriate HCPCS codes. Furthermore, if preoperative planar or tomographic lymphoscintigraphy imaging is performed to visually document the lymphatic drainage pathways prior to surgery, it is coded separately using the corresponding nuclear medicine imaging codes.